Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Active stromelysin-3 (MMP-11) increases MCF-7 survival in three-dimensional Matrigel culture via activation of p42/p44 MAP-kinase.

Fromigué O, Louis K, Wu E, Belhacène N, Loubat A, Shipp M, Auberger P, Mari B.

Int J Cancer. 2003 Sep 1;106(3):355-63.

2.

Group IB secretory phospholipase A2 promotes matrix metalloproteinase-2-mediated cell migration via the phosphatidylinositol 3-kinase and Akt pathway.

Choi YA, Lim HK, Kim JR, Lee CH, Kim YJ, Kang SS, Baek SH.

J Biol Chem. 2004 Aug 27;279(35):36579-85. Epub 2004 Jun 25.

3.
5.

Genistein, a tyrosine kinase inhibitor, enhanced radiosensitivity in human esophageal cancer cell lines in vitro: possible involvement of inhibition of survival signal transduction pathways.

Akimoto T, Nonaka T, Ishikawa H, Sakurai H, Saitoh JI, Takahashi T, Mitsuhashi N.

Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):195-201.

PMID:
11316564
6.

Bradykinin-induced p42/p44 MAPK phosphorylation and cell proliferation via Src, EGF receptors, and PI3-K/Akt in vascular smooth muscle cells.

Yang CM, Lin MI, Hsieh HL, Sun CC, Ma YH, Hsiao LD.

J Cell Physiol. 2005 Jun;203(3):538-46.

PMID:
15573401
11.

Matrix metalloproteinase 1 interacts with neuronal integrins and stimulates dephosphorylation of Akt.

Conant K, St Hillaire C, Nagase H, Visse R, Gary D, Haughey N, Anderson C, Turchan J, Nath A.

J Biol Chem. 2004 Feb 27;279(9):8056-62. Epub 2003 Dec 15.

12.

Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells.

Reddy KB, Krueger JS, Kondapaka SB, Diglio CA.

Int J Cancer. 1999 Jul 19;82(2):268-73.

14.

RNAi-mediated downregulation of radiation-induced MMP-9 leads to apoptosis via activation of ERK and Akt in IOMM-Lee cells.

Gogineni VR, Kargiotis O, Klopfenstein JD, Gujrati M, Dinh DH, Rao JS.

Int J Oncol. 2009 Jan;34(1):209-18.

16.

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.

Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S.

J Cell Physiol. 2006 May;207(2):420-7.

PMID:
16419029
18.
19.

Matrix metalloproteinase inhibitors.

Wojtowicz-Praga SM, Dickson RB, Hawkins MJ.

Invest New Drugs. 1997;15(1):61-75. Review.

PMID:
9195290
20.

Activation of the insulin-like growth factor 1 signaling pathway by the antiapoptotic agents aurintricarboxylic acid and evans blue.

Beery R, Haimsohn M, Wertheim N, Hemi R, Nir U, Karasik A, Kanety H, Geier A.

Endocrinology. 2001 Jul;142(7):3098-107.

PMID:
11416032

Supplemental Content

Support Center